Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 11 , Pages 1815-1820 , November 2009

Potential Clinical Impact of Compounded Versus Noncompounded Intrathecal Baclofen

Presented to the American Academy of Physical Medicine and Rehabilitation, September 26, 2007, Boston, MA.

  • Elizabeth Moberg-Wolff, MD, FAAPMR

      Affiliations

    • Corresponding Author InformationReprint requests to Elizabeth Moberg-Wolff, MD, FAAPMR, 999 N 92nd St, Ste 350 CCC, Milwaukee, WI 53201

References 

  1. Albright AL, Gilmartin R, Swift D, Krach LE, Ivanhoe CB, McLaughlin JF. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg. 2003;98:291–295
  2. Coffey JR, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993;78:226–232
  3. Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SP. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006;87:1509–1515
  4. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099–2109
  5. Ordia JI, Fischer E, Adamski E, et al. Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation. 2002;5:16–24
  6. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–595
  7. Medtronic Inc.. Medtronic Device Registration on File (“What is Medtronic ITB Therapy?”). http://www.medtronic.com/your-health/cerebral-palsy/device/what-is-it/index.htmAccessed: October 8, 2009
  8. Sigg J, Sonntag JC, Li J. Solubility and stability of intrathecal baclofen solutions at high concentrations: implications for chronic use in the synchromed infusion system (White Paper 2007). Minneapolis: Medtronic Neurological; 2007;
  9. Food and Drug Administration Modernization act of 1997 (Public Law 105-115. 105th Congress. Food and Drug Administration). http://www.fda.gov/cder/guidance/105-115.htmAccessed January 10, 2009
  10. Subramaniam P. Limited FDA survey of drug products. 2003;http://www.fda.gov/cder/pharmcomp/survey.htmAccessed January 10, 2009
  11. Azarnoff DL, Lee JC, Lee C, Chandler J, Karlin D. Quality of extemporaneously compounded nitroglycerin ointment. Dis Colon Rectum. 2007;50:509–516
  12. Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis. 2006;43:831–837
  13. Held MR, Begier EM, Beardsley DS, et al. Life-threatening sepsis caused by Burkholderia Cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics. 2006;118:e212–e215
  14. Sunenshine RH, Tan ET, Terashita DM, et al. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis. 2007;45:527–533
  15. Galson S. Federal and state role in pharmacy compounding (FDA congressional testimony Oct 23). 2003;www.fda.gov/ola/2003/pharmacycompound1023.htmlAccessed January 10, 2009
  16. Pegues DA. Improving and enforcing compounding pharmacy practices to protect patients. Clin Infect Dis. 2006;43:838–840
  17. Pharmaceutical considerations—sterile preparations (The United States Pharmacopeia). In: The United States Pharamcopeial Convention. 27th rev. 2004;p. 2350–2370
  18. Kastango E. Blueprint for implementing USP chapter 797 for compounding sterile preparations. Am J Health Syst Pharm. 2004;62:1271–1288
  19. Kastango E, Bradshaw B. USP chapter 797: Establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm. 2004;61:1928–1938
  20. Candy TA, Schneider PJ, Pedersen CA. Impact of United States pharmacopeia chapter 797: results of a national survey. Am J Health Syst Pharm. 2006;63:1336–1343
  21. Shirley KW, Kothare S, Piatt JH, Adirim TA. Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care. 2006;22:258–261
  22. Yeh RN, Nypaver MM, Deegan TJ, Ayyangar R. Baclofen toxicity in an 8-year-old with an intrathecal baclofen pump. J Emerg Med. 2004;26:163–167
  23. Zuckerbraun NS, Ferson SS, Albright AL, Vogeley E. Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care. 2004;20:759–764
  24. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83:735–741
  25. Kinkade K. Pharmacy compounding: report on quality assurance initiatives in the state of Missouri and issues impacting consumer protection (Written testimony before the Health, Education, Labor and Pensions Committee US Senate. Hearing on federal and state role in pharmacy compounding and reconstitutions, exploring the right mix to protect patients. Oct 2003). http://www.fda.gov/ohrms/dockets/dockets/05p0116/05p-0116-cp00001-toc.htmAccessed January 10, 2009
  26. Morris AM, Schneider PJ, Pedersen CA, Mirtallo JM. National survey of quality assurance activities for pharmacy-compounded sterile preparations. Am J Health Syst Pharm. 2003;60:2567–2576
  27. Fitch DP, Hall KW. Survey of sterile product compounding practices in Canadian hospital pharmacies. Can J Hosp Pharm. 1993;46:249–260
  28. Papich MG. Drug compounding for veterinary patients. AAPS J. 2005;7:E281–E287
  29. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169–178
  30. Nicol ME, Holdcroft A. Density of intrathecal agents. Br J Anaesth. 1992;68:60–63
  31. Young D. Outsourced compounding can be problematic (American Society of Health-System Pharmacists News. Dec 2003). http://www.ashp.org/import/News/HealthSystemPharmacyNews/newsarticle.aspx?id=1125Accessed: October 1, 2009

 Medical College of Wisconsin was supported by grant funding from Medtronic Neurologic, Inc, for independent testing of the samples in this study.

 No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated. Moberg-Wolff discloses involvement with Medtronic Neurologic, Inc as a teaching consultant.

PII: S0003-9993(09)00466-3

doi: 10.1016/j.apmr.2009.05.018

Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 11 , Pages 1815-1820 , November 2009

Article Tools

* Image Usage & Resolution